Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Rating of “Moderate Buy” by Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $19.75.

Several analysts have weighed in on MSLE shares. Leerink Partners initiated coverage on Satellos Bioscience in a research report on Monday, April 6th. They set an “outperform” rating and a $20.00 price objective on the stock. Guggenheim started coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. HC Wainwright lifted their price target on Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a research note on Thursday, July 9th.

Satellos Bioscience Price Performance

Shares of MSLE opened at $9.01 on Wednesday. Satellos Bioscience has a 1-year low of $4.64 and a 1-year high of $13.39. The company’s 50-day moving average is $7.03. The company has a market cap of $187.68 million, a price-to-earnings ratio of -5.63 and a beta of 1.53.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, sell-side analysts expect that Satellos Bioscience will post -1.69 earnings per share for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.